BACKGROUND: There are conflicting data about the effects of oral contraceptives on bone mass in young @entity1 . Moreover, amenorrheic @entity1 may also be affected to varying degrees by @entity2331 . Both conditions (oral contraceptive use and @entity2588 ) are not infrequent in @entity1 during their reproductive years. AIM: To evaluate the safety for bone mass of two oral contraceptives, one containing @entity3429 and the other containing desogestrel. METHODS: A total of 67 @entity1 between 19 and 29 years of age were studied. Of these @entity1 , 35 were selected to receive an oral contraceptive containing 35 mg @entity2082 and 2 mg @entity3429 . A second group of 32 @entity1 received an oral contraceptive containing 30 mg @entity2082 and 150 mg desogestrel for 2 years. Immediately before and after the 12th and 24th months of therapy, bone mineral density was assessed by dual X-ray absorptiometry, and hormonal profiles and Ferriman-Gallwey scores were evaluated. RESULTS: After the 2-year follow-up, all subjects showed regular cycles, no pregnancies, and no changes in bone mass density. In addition, hirsute subjects showed a decrease of almost 42% in hirsutism scores. CONCLUSION: Oral contraceptives containing @entity3429 or desogestrel in the studied doses have no deleterious effects on bone marrow.

Effects on bone mass of two oral contraceptives containing XXXX and @entity3429 or desogestrel: results of a 2-year follow-up.

@entity1 :: ('9606', 'Species') :: ['women'] @entity3429 :: ('MESH:D017373', 'Chemical') :: ['cyproterone acetate'] @entity2082 :: ('MESH:D004997', 'Chemical') :: ['ethinylestradiol'] @entity2331 :: ('MESH:D001851', 'Disease') :: ['osteopenia'] @entity2588 :: ('MESH:D000568', 'Disease') :: ['amenorrhea']
@entity2082 :: (MESH:D004997,Chemical) :: ['ethinylestradiol']
